We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Geron (GERN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Geron (GERN - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Geron is one of 1187 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Geron is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for GERN's full-year earnings has moved 3.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, GERN has gained about 90.2% so far this year. Meanwhile, the Medical sector has returned an average of -21.4% on a year-to-date basis. This shows that Geron is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Kiniksa Pharmaceuticals, Ltd. (KNSA - Free Report) . The stock has returned 6.3% year-to-date.
In Kiniksa Pharmaceuticals, Ltd.'s case, the consensus EPS estimate for the current year increased 66.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Geron belongs to the Medical - Biomedical and Genetics industry, which includes 562 individual stocks and currently sits at #58 in the Zacks Industry Rank. On average, this group has lost an average of 24.8% so far this year, meaning that GERN is performing better in terms of year-to-date returns. Kiniksa Pharmaceuticals, Ltd. is also part of the same industry.
Geron and Kiniksa Pharmaceuticals, Ltd. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Geron (GERN) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Geron (GERN - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Geron is one of 1187 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Geron is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for GERN's full-year earnings has moved 3.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, GERN has gained about 90.2% so far this year. Meanwhile, the Medical sector has returned an average of -21.4% on a year-to-date basis. This shows that Geron is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Kiniksa Pharmaceuticals, Ltd. (KNSA - Free Report) . The stock has returned 6.3% year-to-date.
In Kiniksa Pharmaceuticals, Ltd.'s case, the consensus EPS estimate for the current year increased 66.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Geron belongs to the Medical - Biomedical and Genetics industry, which includes 562 individual stocks and currently sits at #58 in the Zacks Industry Rank. On average, this group has lost an average of 24.8% so far this year, meaning that GERN is performing better in terms of year-to-date returns. Kiniksa Pharmaceuticals, Ltd. is also part of the same industry.
Geron and Kiniksa Pharmaceuticals, Ltd. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.